Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma

Trial Profile

An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide; Melphalan; Pomalidomide; Prednisone; Prednisone; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational
  • Acronyms EQUULEUS
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 22 May 2019 Results assessing indirect comparison analysis of individual patient data from this and other two studies NCT02654132 and NCT01464034, presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 12 May 2019 Results assessing Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (n=85) published in the Blood
    • 27 Feb 2019 Planned End Date changed from 12 Jun 2020 to 31 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top